-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RlKOJ6OvrAQP8fq3hb4MhyJEohExWj9ktjAhBSF/rzaf536sf2Fw7NQYbKavbK63
 Yf7NQp/PWdja2WAZPGWTaQ==

<SEC-DOCUMENT>0000950123-04-015089.txt : 20041222
<SEC-HEADER>0000950123-04-015089.hdr.sgml : 20041222
<ACCEPTANCE-DATETIME>20041222161049
ACCESSION NUMBER:		0000950123-04-015089
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20041222
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20041222
DATE AS OF CHANGE:		20041222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EYETECH PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001115285
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				134104684
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50516
		FILM NUMBER:		041221040

	BUSINESS ADDRESS:	
		STREET 1:		3 TIMES SQUARE
		STREET 2:		12TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		2128243100

	MAIL ADDRESS:	
		STREET 1:		3 TIMES SQUARE
		STREET 2:		12TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>y69746ke8vk.txt
<DESCRIPTION>FORM 8-K
<TEXT>
<PAGE>
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  ------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): December 22, 2004


                          Eyetech Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

<TABLE>
<S>                                <C>                      <C>
          Delaware                     000-50516                 13-4104684
- ------------------------------     ---------------------    --------------------
(State or Other Jurisdiction          (Commission             (I.R.S. Employer
     of Incorporation)               File Numbers)          Identification No.)
</TABLE>


<TABLE>
<S>                                                         <C>
                  3 Times Square, 12th Floor
                         New York, NY                               10036
- --------------------------------------------------------    --------------------
           (Address of Principal Executive Offices)               (Zip Code)
</TABLE>


       Registrant's telephone number, including area code: (212) 824-3100


- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     [ ]   Written communications pursuant to Rule 425 under the Securities Act
           (17 CFR 230.425)

     [ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
           (17 CFR 240.14a-12)

     [ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
           Exchange Act (17 CFR 240.14d-2(b))

     [ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
           Exchange Act (17 CFR 240.13e-4(c))

================================================================================


<PAGE>
ITEM 7.01. REGULATION FD DISCLOSURE

     On December 22, 2004, Eyetech Pharmaceuticals, Inc. announced the list
price for Macugen(R) (pegaptanib sodium injection). The full text of the press
release announcing the list price is filed as Exhibit 99.1 to this Current
Report on Form 8-K.


<PAGE>
                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  December 22, 2004             EYETECH PHARMACEUTICALS, INC.


                                     By:        /s/ Glenn P. Sblendorio
                                              ----------------------------------
                                     Name:    Glenn P. Sblendorio
                                     Title:   Senior Vice President, Finance and
                                              Chief Financial Officer


<PAGE>
                                  EXHIBIT INDEX

<TABLE>
<CAPTION>
Exhibit No.      Description
- -----------      -----------
<S>              <C>
99.1             Press release dated December 22, 2004, of Eyetech
                 Pharmaceuticals, Inc. announcing the list price of Macugen(R)
                 (pegaptanib sodium injection)
</TABLE>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>y69746kexv99w1.txt
<DESCRIPTION>PRESS RELEASE
<TEXT>
<PAGE>
[EYETECH LOGO]

FOR IMMEDIATE RELEASE
- ---------------------

Contact:

Karin Hehenberger, M.D., Ph.D.
Senior Director of Scientific and External Affairs
Office: 212 824 3176
Facsimile: 212 824 3240
Email: karin.hehenberger@eyetech.com
www.eyetech.com

                  Eyetech Pharmaceuticals, Inc. Announces Price
                  for Macugen(R) (pegaptanib sodium injection)
                    Will Host Live Discussion of Launch Plan

New York, NY - December 22, 2004 - Eyetech Pharmaceuticals, Inc. (Nasdaq: EYET)
today announced that the list price for Macugen(R) (pegaptanib sodium injection)
will be $995 per injection. Macugen was approved by the FDA on December 17, 2004
for use in the treatment of neovascular (wet) age-related macular degeneration,
an eye disease associated with aging that destroys central vision.

Eyetech management will host a conference call regarding the pricing strategy
and the launch plan for Macugen on Wednesday January 5, 2005 at 8:30AM EST,
before the US markets open. Live audio of the call will be available to
investors, members of the news media and the general public by dialing
888-275-0218 (in the United States) or 706-679-7756 (internationally). A
playback of this event will be available through January 19, 2005 by dialing
800-642-1687 (within the United States) or 706-645-9291 (internationally). The
passcode for this replay will be 3062807. In addition, this discussion will be
broadcasted simultaneously over the Internet and the webcast can be accessed by
logging on to the Investor Relations section of our corporate website at
www.eyetech.com. An archived version of the webcast will be available at the
same location through January 19, 2005.

About Eyetech Pharmaceuticals, Inc.
Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in
the development and commercialization of novel therapeutics to treat diseases of
the eye.

<PAGE>

Eyetech's initial focus is on diseases affecting the back of the eye.
Eyetech is commercializing and further developing Macugen(R) (pegaptanib sodium
injection) with Pfizer Inc for the treatment of neovascular AMD. Macugen is also
being studied for the treatment of diabetic macular edema and retinal vein
occlusion.

Safe Harbor Statement
This press release contains a forward-looking statement that involves
substantial risks and uncertainties. You should not place undue reliance on our
forward-looking statements. Various important factors could cause actual results
or events to differ materially from the forward-looking statement that we make,
including risks related to: achieving acceptance of Macugen by the medical
community, by patients receiving therapy and by third party payors; supplying
sufficient quantities of Macugen to meet anticipated market demand; the impact
of competitive products; our dependence on third parties to manufacture Macugen;
new information arising out of clinical trial results; and the success of
Macugen's launch generally. These and other risks in investing in Eyetech are
described in greater detail in the "Risk Factors" section of our most recent
quarterly report on Form 10-Q filed with the SEC. We do not assume any
obligation to update any forward-looking statements.

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
